Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Once again, our agenda is modest. We plan to hang with a short person or two, promenade with the official mascot, and check in on the Pharmalot ancestors. And what about you? The great outdoors remains appealing, especially if you want to search for pumpkins and apples. Along the way, you could stop to drop off your ballot. You may want to help the economy by stocking up on sweaters. Or reach out to older folks feeling isolated. Well, whatever you do, have a grand time. But be safe — wear a mask. Enjoy, and see you soon. …

Infusing hospitalized Covid-19 patients with blood plasma from people who recovered had no effect on whether patients got sicker or died, STAT says, citing the first completed randomized trial of the treatments. The study could re-energize the debate over whether blood plasma is an effective treatment for the disease. An earlier study, run by the Mayo Clinic, showed blood plasma did yield some benefit, leading the Food and Drug Administration to grant emergency access to the therapy in August. That trial, however, did not have a control arm.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy